Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-label, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet Versus Epoetin Alfa Injection for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) on Dialysis (DREAM-D)

NCT04215120 is registered in ClinicalTrials.gov with Zydus Lifesciences Limited as lead sponsor.

NCT NCT04215120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04215120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-label, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet Versus Epoetin Alfa Injection for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) on Dialysis (DREAM-D)
Lead sponsor
Zydus Lifesciences Limited
Phase
Phase 3
Overall status
Completed
Start date
January 4, 2020
Completion date
September 2, 2021
Enrollment
392 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease stage 5 on dialysis